AdDIT Follow Up
Research type
Research Study
Full title
Tracking of risk for diabetic nephropathy and cardiovascular disease in young people with Type 1 diabetes recruited to the AdDIT study
IRAS ID
172067
Contact name
Stephen Kelleher
Contact email
Sponsor organisation
Cambridge University Hospitals NHS Foundation Trust and University of Cambridge
ISRCTN Number
ISRCTN91419926
Duration of Study in the UK
4 years, 11 months, 28 days
Research summary
Young people with type 1 diabetes(T1D) are at an increased risk of developing cardiovascular disease (CVD) and diabetic nephropathy (DN). Adolescence, and specifically the period between age 10 and 25 is a vulnerable period, which we know has a major impact on long term CVD and DN risk. The AdDIT Trial explored the effects of early detection of risk and interventions with ACE inhibitors and statins in a population of over 800 young people aged 10-16 years. The results of AdDIT will be available in 2016 and will provide robust data regarding these primary therapeutic interventions. It also offers a unique cohort to explore other aspects of DN and CVD risk. Continued follow up of this cohort will provide a rich seam to evaluate the impact of puberty, glycaemia and potentially the metabolic memory which determines later DN/CVD outcomes.
REC name
East of England - Cambridge South Research Ethics Committee
REC reference
16/EE/0053
Date of REC Opinion
8 Mar 2016
REC opinion
Favourable Opinion